Company Overview and News

 
Midcap cement Q1 review: Volumes showing strong uptrend; Prefer Ramco

2018-09-03 moneycontrol
The cement sector started FY19 on a strong note as most companies recorded healthy volume growth in Q1 FY19. On the cost front, companies are showing signs of minor improvement on a quarter-on-quarter (QoQ) basis as rising input pressures appear to have stabilised.
500380 500260 SAGCEM RMCTY RAMCOCEM 502090 JKLAKSHMI

 
The Ramco Cements Limited - Disclosure under SEBI Takeover Regulations

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Shareholders meeting

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Disclosure under SEBI Takeover Regulations

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Disclosure under SEBI Takeover Regulations

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Disclosure under SEBI Takeover Regulations

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
Kerala floods impact: Cement demand, prices to take a hit

2018-08-23 livemint
Cement demand in Kerala, which is estimated to contribute around 13% to overall sales volumes in southern India, would get hit in the near term due to the Kerala floods. Consequently, prices in this region would remain muted. A recent dealer channel check by domestic broking house Kotak Institutional Equities Ltd showed that prices of the building material in south India declined to ₹ 345/bag in August from ₹ 347/bag in July.
500260 RMCTY RAMCOCEM INDIACEM 530005

 
The Ramco Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Disclosure under SEBI Takeover Regulations

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Disclosure under SEBI Takeover Regulations

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Shareholders meeting

2018-08-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

 
The Ramco Cements Limited - Shareholders meeting

2018-08-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500260 RMCTY RAMCOCEM

1
ONGC, GIC Housing, MOIL, Pfizer results

2018-08-01 thehindubusinessline
Seventy three companies including Akzo Nobel India, Avantel, Capital First, Deepak Nitrite, GE Power, GIC Housing Finance, Godrej Properties, Ibulls Housing Fin, International Paper, JK Lakshmi Cement, Mahindra Logistics, Mahindra Holidays, Manpasand, Majesco, Marico, MOIL, ONGC, Pfizer, Ramco Cements, Rane Holdings, Raunaq EPC, Transport Corporation, Torrent Pharma and Uttam Sugar will declare their quarterly results for the April-June period on Thursday
GICHSGFIN BAJAJ-AUTO 500710 532938 533150 RMCTY INPAP CAPF 532977 511676 DEEPAKNI 500380 500260 GODREJPROP IP RANEHOLDIN RAMCOCEM AKZOINDIA JKLAKSHMI 505800 506401

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...